Stephens Inc. AR Raises Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Stephens Inc. AR increased its stake in shares of Repligen Co. (NASDAQ:RGEN) by 3.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 46,700 shares of the biotechnology company’s stock after purchasing an additional 1,680 shares during the quarter. Stephens Inc. AR’s holdings in Repligen were worth $6,950,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in RGEN. Andra AP fonden purchased a new stake in Repligen in the second quarter valued at about $25,000. International Assets Investment Management LLC purchased a new stake in Repligen in the second quarter valued at about $33,000. UMB Bank n.a. raised its stake in Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 130 shares during the last quarter. Lazard Asset Management LLC raised its stake in Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 136 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 127 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Stock Up 3.2 %

Repligen stock opened at $138.61 on Friday. The firm has a market cap of $7.76 billion, a price-to-earnings ratio of -3,464.38, a price-to-earnings-growth ratio of 3.92 and a beta of 0.95. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13. The business’s 50-day moving average price is $142.04 and its 200 day moving average price is $145.96. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. The firm had revenue of $154.07 million for the quarter, compared to analyst estimates of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. Repligen’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same period last year, the company earned $0.53 earnings per share. As a group, sell-side analysts anticipate that Repligen Co. will post 1.45 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on RGEN shares. Stephens reiterated an “overweight” rating and issued a $170.00 price target on shares of Repligen in a research note on Tuesday, July 30th. JPMorgan Chase & Co. increased their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Benchmark reissued a “hold” rating on shares of Repligen in a report on Monday, August 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. Finally, UBS Group cut their price objective on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.